NCT01762150 - Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

December 31, 2016

Study Completion Date

June 30, 2018

Conditions

Renal Cell Carcinoma

Interventions

DRUG

Sorafenib

Sorafenib 400mg BID by oral until progressed;

DRUG

Gemcitabine

Gemcitabine: 1000mg/m2, administered by intravenous drip for 30\~60min on Day 1 and 8,for 4 cycles;

DRUG

Cisplatin

Cisplatin: 25mg/m2, administered by intravenous drip on Day 1-3, with appropriate liquid hydration,for 4 cycles.

Trial Locations (5)

Beijing Cancer Hospital, Beijing

Shenyang general hospital of Shenyang military command, Shenyang

Sun Yat-sen university cancer center, Guangzhou

West China Hospital, Chengdu

Xijing Hospital, Xi’an